Marinus Pharmaceuticals (NASDAQ:MRNS) Price Target Increased to $22.00 by Analysts at JMP Securities

Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) had its price objective lifted by investment analysts at JMP Securities from $21.00 to $22.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has a “market outperform” rating on the biopharmaceutical company’s stock. JMP Securities’ price target suggests a potential upside of 151.72% from the […]

Related Keywords

,Life Insurance Co ,Zacks Investment Research ,Marinus Pharmaceuticals Company Profile Get Rating ,Analyst Recommendations For Marinus Pharmaceuticals ,Invesco Ltd ,Marinus Pharmaceuticals ,Walleye Capital ,Marinus Pharmaceuticals Inc ,Citigroup Inc ,Get Rating ,Truist Financial ,Pharmaceuticals Company Profile ,Nasdaq Mrns ,Mrns ,Medical ,Boost Price Target ,Jmp Securities ,